Molecular Medicine Reports 18: 2661-2668, 2018

Abstract. Ovarian cancer is the most lethal gynecological cancer and its metastasis leads to a poor prognosis. The present study was designed to elucidate how microRNA (miR)-665 regulates the proliferation and migration of ovarian tumor cells. Reverse transcription-polymerase chain reaction (RT-PCR) demonstrated that miR-665 expression was decreased in ovarian cancer tissues. Increased expression of miR-665 suppressed the growth and migration of ovarian cancer cells, whereas the downregulated expression of miR-665 led to the opposite results. Bioinformatics tools identified homeobox A10 (HOXA10) as a target of miR-665. Following miR-665 overexpression, HOXA10 protein expression was significantly reduced. A dual luciferase assay revealed that miR-665 bound to the 3'-untranslated region of HOXA10. Immunohistochemistry and RT-PCR revealed that the expression of HOXA10 was negatively correlated with the expression of miR-665. It was concluded that miR-665 targets HOXA10 and may act as a tumor-suppressing gene in ovarian cancer. This pathway may be involved in the development and metastasis of ovarian cancer.

Introduction

Epithelial ovarian cancer (EOC) is a major cause for malignancy-associated female mortality (1). The mortality rate is frequently increased by a delay in diagnosis and drug resistance (2). Investigating the mechanisms behind EOC initiation and progression can help us to find a therapeutic target.

MicroRNAs (miRs), non-coding RNAs with a length of 20-24 nucleotides, regulate gene expression by inhibiting translation or degrading messenger RNA (3). Increasing evidence reveals that miRs regulate cellular processes, including proliferation, differentiation and apoptosis (3-5). A number of miRs are associated with ovarian cancer, and may regulate tumor progression, function as potential prognostic markers and contribute to drug resistance (6-9). The functions of miRs in carcinogenesis have been illustrated in multiple studies. For example, miR-224, as an oncogene in EOC, improves cancer cell proliferation by downregulating KILLIN expression (10). By targeting pyruvate dehydrogenase E1 β subunit, miR‑203 promotes the proliferation and migration of EOC cells (11). Other miRs function as tumor suppressors expressed (12,13). For example, by targeting cyclin dependent kinase (CDK1), miR-490-3p inhibits the proliferation, migration and invasion of EOC cells (12). miR -101 suppresses the expression of the suppressor of cytokine signaling 2 gene and inhibits the proliferation and invasion of EOC cells (13). Among them, miR-655 was the focus of the present study as it has been demonstrated to play a role in certain malignancies, including esophageal squamous cell carcinoma (14), bladder urothelial carcinoma (15) and gastric signet ring cell carcinoma (16). Currently, to the best of our knowledge, no studies have been conducted to investigate the association between miR-665 and EOC.

Homeobox A10 (HOXA10), one member of the homeobox gene family, acts as a transcription factor in embryonic development (17). The aberrant expression of HOXA10 can be demonstrated by the downregulation of HOXA10 in cancer cellular processes, including cell proliferation, epithelial-mesenchymal transition, apoptosis and drug resistance (6,18-22). HOXA10 was demonstrated to participate in G1 phase arrest of endometrial cancer that may be caused by P21 expression (23). It was hypothesized that miR-665 can regulate HOXA10 expression, based on the data from PicTar, TargetScan and miRBase. However, the role of miR-665 in the development of EOC and its association with HOXA10 remains uninvestigated.

In the present study, the expression of miR-665 in human EOC and normal ovary tissues were compared, and the impact of miR-665 expression on cell proliferation and migration in vitro was investigated. The results of the present study suggested that miR-665 serves a suppressive role in human EOC pathogenesis.
Materials and methods

Tissue samples and cell lines. Informed consent was obtained from each patient. The present study was approved by the Institutional Ethic Committee of Nanjing Medical University (Nanjing, China). Tissues from EOC patients were frozen immediately and stored at -80˚C. EOC tissue specimens (n=28) and normal ovarian tissue specimens (n=15) were collected from patients (age range, 24-73) who underwent surgery at the Department of Gynecology at the First Affiliated Hospital of Nanjing Medical University (Nanjing, China) between December 2014 and December 2015. EOC cell lines (HO8910 and OVCAR-3) and 293T cells were purchased from American Type Culture Collection (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium ( Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin, and 100 µg/ml (Beijing Solarbio Science and Technology Co., Ltd., Beijing, China) at 37˚C with 5% CO₂.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA was extracted from ovarian tissues and ovarian cancer cell lines using TRIzol reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA) following the manufacturer's protocol. Following isolation, the integrity of RNA was determined using Agilent Bioanalyzer 2100 and RNA 6000 Nano kit (Agilent Technologies, Inc., Santa Clara, CA, USA). According to the manufacturer's protocol, single-stranded complementary DNA (cDNA) was synthesized from 1 µg RNA in a 20 µl reaction volume with the High-Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific, Inc.), at 25˚C for 10 min, 37˚C for 120 min and 85˚C for 5 sec, followed by a 4˚C hold. Quantification of miR and mRNA was carried out using a SYBR Green PCR kit (Thermo Fisher Scientific, Inc.), and the cycle quantification (Cq) of each gene was recorded. The relative expression of miR-665 and HOXA10 was normalized to U6, and calculated using the 2^(-ΔΔCq) method (ΔCq=ΔCq_target gene-ΔCq_internal control) (24). The qPCR was performed using the following parameters: 95˚C, 10 min; 40 cycles, 95˚C, 15 sec; 67˚C, 30 sec; 72˚C, 30 sec; and 72˚C, 5 min. The primers used are illustrated in Table I.

Protein extraction and western blotting. At 48 h following transfection, the cells were harvested, washed twice with phosphate-buffered saline, lysed using M-PER™ Mammalian Protein Extraction reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 0.01% protease and phosphatase inhibitor, and incubated on ice for 30 min. The cell lysate was centrifuged at 4˚C and 12,000 x g for 15 min. Protein concentrations were determined by a bicinchoninic acid protein assay (Beyotime Institute of Biotechnology, Haimen, China). The supernatant (50 µg) of total protein was run on 10% SDS-PAGE and transferred electrophoretically to a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). Following blocking in Western Blocking Reagent (10%; Hoffman; Roche Diagnostics, Basel, Switzerland) for 15 min at room temperature, the membrane was incubated overnight at 4˚C with polyclonal rabbit anti-human HOXA10 (1:1,000; Abcam, Cambridge, MA, USA; cat. no. ab90641) and mouse anti-human β-actin (1:10,000; cat. no. ab49900; Abcam), respectively. The membranes were washed with 1X Tris-buffered saline containing 0.1% Tween-20 (TBST), incubated with the horseradish peroxidase (HRP)-conjugated anti-rabbit IgG secondary antibody (1:1,000; cat. no. 7074; Cell Signaling Technology, Inc.) at room temperature for 1 h. Membranes were washed again with TBST three times for 10 min each, prior to visualization and analysis using the Odyssey IR imaging system (LI-COR Biosciences, Lincoln, NE, USA).

Bioinformatics analysis. To investigate the target genes of miR-665, TargetScan version 7.1 (http://www.targetscan.org), PicTar 5 (https://pictar.mdc-berlin.de/) and miRBase release 22 (http://www.mirbase.org/) were used to predict the potential target gene of miR-665.

Transwell migration assay. Following being placed into a 24-well plate, the migration assays of OVCAR-3 and HO8910 cells were carried out using Transwell chambers (EMD Millipore). For the migration assay, a total of 1x10⁵ cells were resuspended in 200 µl serum-free medium and placed in the top chambers. RPMI-1640 medium (600 µl) containing 10% FBS was added into the bottom chambers. Cells were incubated for another 20 h at 37˚C with 5% CO₂. The cells were fixed with 4% polyoxymethylene following the incubation for 20 min at room temperature, stained with 0.1% crystal violet for 20 min and observed using a light microscope (magnification, x100; Olympus Corporation, Tokyo, Japan). The numbers of migrated cells were calculated from five randomly selected fields.

Colony formation assay. Cells were transfected with NC, miR-665, as described above. Then 24 h later, transfected cells were trypsinized, counted and replated at a concentration of 500 cells/well. Following another 10 days, colonies formed by the surviving cells were fixed with 3.7% methanol for 20 min at room temperature, stained with 0.1% crystal violet for 20 min at room temperature and counted. Colonies containing ≥50 cells were scored. Each assay was performed in triplicate.

CCK-8 assay. The cell proliferation reagent WST-8 (Roche Diagnostics GmbH, Mannheim, Germany) was used to measure cell growth. Cells were seeded into 96-well microtiter plates (Corning Inc., Corning, NY, USA) at a density of 1.0x10⁴ cells/well. CCK-8 was added to each well according to the manufacturer’s protocol. Following incubation at 37˚C with 5% CO₂ for 2 h, the absorbance of the converted dye was detected at 450 nm to determine the cellular viability.

Dual-luciferase reporter assay. The 3'-untranslated regions (3'-UTRs) of human HOXA10 cDNA with the potential target sites for miR-665 were synthesized and inserted at the XbaI site downstream of the luciferase gene in the pGL3-control (Promega Corporation, Madison, WI, USA) vector by Integrated Biotech Solutions Co., Ltd., (Shanghai, China).

At 24 h prior to transfection, cells were seeded in 24-well plates (1.5x10⁴ cells/well). Then, 200 ng of pGL3-HOXA10-3'-UTR and 80 ng of pRL-TK (Promega...
Corporation) were co-transfected with 60 pmol of miR-665 mimic or NC using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. At 24 h following the transfection, the Dual-luciferase assay system (Promega Corporation) was used to determine luciferase activity as previously described (6). The firefly luciferase activity in each well was normalized to that of the Renilla luciferase. Three independent experiments were performed in duplicate. The sequence of 3’ UTR of human HOXA10 cDNA containing the putative target site for the miR-665; the underlined, italicized area indicates the putative target site for miR-665: 5’-TGAATCTCCAGGCGAAGCGTTTTTTTC ACTTCCGGAGCGCTGTCCTCCCCCTCTGCTGTCAG GTCTGCAGGAACCTGCACTGTGAGACCCT GTTCCTCCCTCCCCACACCTGCACCTGTCGAGGGGT TGATCTGTGACGGCTGTTTTGTTCTGACTTTTGG TTCTTTTTGTTGTTGTTGTTGTTTGTGT GGGGGGGGAAAAAGGCCATATCATGCTAATTTCT TATAGAGATA-3’.  

**Immunohistochemistry.** The tissues were fixed in 10% formalin for 24 h at room temperature, embedded in paraffin and 4 µm thick sections were prepared. Microwave irradiation in 10 mol/l citrate buffer (pH 6.0) was used for antigen retrieval for tissue slides incubated with a HOXA10 antibody (1:500; cat. no. ab90641; Abcam) at 4˚C overnight, followed by incubation with a HRP-conjugated secondary antibody (1:1,000; cat. no. ab6721; Abcam) for 1 h at room temperature. The staining was repeated if the result was uncertain. Immunostaining of the slides was objectively evaluated by two pathologists under a light microscope (magnification, x200; Olympus Corporation, Tokyo, Japan). Discordant scores were reevaluated until consensus was reached. The level of positive HOXA10 expression in cancer cells was analyzed by HMIAS-2000 automatic medical color image analysis system (Qianping Image Technology Co., Ltd., Wuhan, China). HOXA10 staining was determined semiquantitatively according to the staining intensity observed (0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining) and the percentage of positive cells (0, none or <10; 1, 11-25; 2, 26-50; and 3, 51-75%; 4, >75%). Scores of 0-3 were considered to indicate negative expression, and scores of 3-12 were considered to indicate positive expression. Cells were counted in at least three randomly selected fields (magnification, x200) in the tumor areas.  

**Statistical analysis.** All experiments were repeated three times independently. The results were summarized as the mean ± standard error. Independent sample t-tests were performed to compare differences between two groups with SPSS 19.0 software (IBM Corp., Armonk, NY, USA). Spearman’s correlation test was used to analyze the correlation between miR-665 and HOXA10 expression. P<0.05 was considered to indicate a statistically significant difference.  

**Results**  

**Expression level of HOXA10 increases in EOC tissues.** Immunohistochemical staining was used to determine the level of HOXA10 expression in both normal and ovarian cancer tissues. HOXA10 expression of 15 EOC specimens and 8 normal specimens were analyzed in the present study. Immunohistochemical staining identified that the HOXA10 protein levels were significantly increased in the ovarian cancer tissues compared with the normal tissues (P<0.01; Fig. 1).  

miR-665 targets the 3'-UTR of HOXA10. TargetScan7.1 (http://www.targetscan.org) was used to predict whether HOXA10 is targeted by miR-665 (Fig. 2A). In the 293T cell line, relative activity of luciferase was significantly decreased (P<0.01) following the co-transfection of the pGL3-HOXA10-3'-UTR vector with the miR-665 mimic, but not following the co-transfection of pGL3-HOXA10-3'-UTR vector with mimic NC, suggesting that HOXA10 is the target gene of miR-665 (Fig. 2B). Western blotting was performed to confirm the downregulation of the HOXA10 protein following the miR-665 transfection in HO8910 and OVCA-3 EOC cells. The protein expression level of HOXA10 significantly decreased in miR-665-transfected cells, compared with cells transfected with miR-NC (P<0.01; Fig. 2C and D). Then
whether HOXA10 is the target of miR-665 was investigated. A luciferase reporter vector was constructed with the target sites of putative HOXA10 3'UTR (luciferase gene) located in the downstream of miR-665. The luciferase reporter vector,
miR-665 mimic and mimic NC was then transfected into 293T cells.

miR-665 is negatively associated with HOXA10. qPCR was used to determine the expression of miR-665 in 28 EOC specimens and 15 normal specimens. Compared with normal tissues, expression level of miR-665 significantly dropped in ovarian cancer tissues, suggesting that miR-665 is down-regulated in ovarian cancer tissues and may be involved in the development of ovarian cancer (P<0.01; Fig. 3A). A significant inverse correlation (R²=0.7496; P<0.01) was observed between miR-665 and HOXA10 using Spearman's correlation analysis (Fig. 3B).

miR-665 suppresses cell growth in vitro. HO8910 and OVCAR-3 cells were transfected with the miR-665 mimic. Subsequently, CCK-8 assays were performed to determine the impact of miR-665 on the proliferation of ovarian cancer cells. The results identified that increased expression of miR-665 significantly suppressed the proliferation of ovarian cancer cells in both cell lines (P<0.05; Fig. 4A and B). The colony formation capacity of HO8910 and OVCAR-3 cells transfected with miR-665 mimic was significantly inhibited compared with the miR-NC group (P<0.05; Fig. 4C and D). These results demonstrated that miR-665 inhibits the proliferative ability of HO8910 and OVCAR-3 cells.

miR-665 suppresses the migration of ovarian cancer cells. Transwell migration assay demonstrated that miR-665-overexpressed HO8910 and OVCAR-3 cells exhibited a significantly decreased ability to migrate compared with the control cells (P<0.05; Fig. 5).

Inhibition of miR-665 promotes the growth and migration of ovarian cancer cell lines. The colony formation rate of HO8910 and OVCAR-3 cells transfected with miR-665 inhibitor, was significantly increased, compared to cells transfected with the miR-NC inhibitor (P<0.05; Fig. 6A and B). The migratory abilities of miR-665-downregulated HO8910 and OVCAR-3 cells were significantly enhanced compared with the miR-NC inhibitor (P<0.05; Fig. 6C and D).

Discussion

Ovarian cancer is the most lethal cancer for women, with an overall survival rate of ~35% (25). Although modified chemotherapy can improve the prognosis, its effectiveness has reached its limit. Consequently, novel therapies, such as targeted therapy combined with standard treatment, are being investigated in clinical trials (26). In these trials, predictive markers can be used to personalize and optimize the therapeutic strategy for ovarian cancer (27).

miRs modulate gene expression in a post-transcriptional manner either by inhibiting translation or destroying the target mRNA (28). miRs are aberrantly expressed in ovarian cancer. For example, the expression of miR-145 is significantly reduced in human ovarian cancer tissues, leading to relapse and poorer outcomes of ovarian cancer (29). miR-490-3p overexpression inhibits the proliferation, migration and invasion of tumor cells by directly targeting CDK1 (12). In addition, miR-497 downregulation triggers chemotherapy resistance in ovarian cancer cells (30). The level of miR-125b expression in ovarian cancer tissue is significantly lower compared with normal ovarian tissues; the increased expression of miR-125b induces cell cycle arrest and inhibits the proliferation and clonal formation of ovarian cancer cells by targeting BCL-3 (31).

In carcinogenesis, miR-665 demonstrates diverse functions (14-16) that are co-regulated by its targets (32). miR-665, located at 14q32.2, with a length of 20 amino acids, can inhibit B7-H3 expression. However, the underlying mechanism remains uninvestigated. In the present study, the analysis of RNA expression revealed that the expression of hsa-miR-665 was decreased in EOC, which is consistent with the results of a previous study on breast cancer (33). Therefore, it is hypothesized that miR-665 may function as a tumor-suppressor gene in ovarian cancer. Certain studies demonstrated that miR-665 expression was dysregulated in a number of types of cancer, including esophageal squamous cell carcinoma (14), bladder urothelial carcinoma (15) and gastric signet ring cell carcinoma (16).

HOXA10, from the homeobox gene family, functions as a transcription factor in embryonic development (17). It has been suggested that HOXA10 acts as a key factor in endometrial receptivity and embryo implantation, and is expressed in endometrial glandular epithelium and mesenchymal cells in normal humans (34). The HOXA10 expression level in the middle and late stages of secretion is increased compared with the period of endometrial proliferation and the early stage of secretion (35). As the progesterone concentration rises during implantation and embryonic circulation, the level of HOXA10 gradually reaches a peak, indicating that HOX genes regulate endometrial development and embryonic planting (35,36). In addition, HOXA10 is highly expressed in endometrioid, clear or mucinous cells, but not in serous epithelial ovary cancer cells (37,38). Aberrant HOX gene expression has been reported in several types of cancer, including glioblastoma (39), oral cancer and gastric cancer (21,22,40). Increased expression of HOXA10 promotes the proliferation, migration and invasion of clear cell adenocarcinoma of the ovary, reducing the survival impact of miR-665 on the proliferation of ovarian cancer cells.
The present study identified that miR-665 was downregulated and negatively correlated with the expression of HOXA10 in ovarian tumor tissues, indicating that miR-665 may be a tumor suppressor gene in the development of ovarian cancer and a potential therapeutic target for ovarian cancer.

In the present study, the RT-qPCR results demonstrated that miR-665 was downregulated in ovarian cancer tissues compared with normal tissues. Immunohistochemistry revealed that HOXA10 was overexpressed in ovarian cancer tissues and this expression was negatively correlated with the expression of miR-665. It was also demonstrated that miR-665 suppressed the proliferation and migration of cell lines, whereas the downregulation of miR-665 led to the opposite effect, as it bound to the 3′-UTR of HOXA10, and downregulated HOX10 by reducing HOXA10 protein levels. Further studies are needed to elucidate the mechanism of HOXA10 silencing.

The present study investigated the expression and biological function of miR-665 in ovarian cancer. miR-665 downregulated the expression of HOXA10 and weakened the ability of ovarian cancer cells to proliferate and migrate. miR-665, through targeting HOXA10, serves as a suppressor gene in ovarian cancer. Therefore, therapeutic miR that mimics miR-665 could possibly be developed to treat ovarian cancer.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Nature Science Foundation of China (grant nos. 81472442...
and 81272871) and the Postgraduate Research & Practice Innovation Program of Jiangsu Province (grant no. JX22013366)

Availability of data and materials
Not applicable.

Authors' contributions
Conceived and designed the experiments: WJC. Performed the experiments: JHL, YJ. Analyzed the data and wrote the manuscript: JHL, YJ, YCW. Performed part of the experiments and bioinformatics analyses: SLZ, ST. All authors read and approved the final manuscript.
Ethics approval and consent to participate

The study was approved by the Ethics Committee of the Nanjing Medical University and samples were obtained with informed consent from all patients.

Patient consent for publication

Informed consent was obtained from all patients.

Competing interests

The authors declare that they have no competing interests.

References

1. Xian H, Xian Y, Liu L, Wang Y, Je J and Huang J: Expression of β-nerve growth factor and homeobox A10 in experimental cryptorchidism treated with exogenous nerve growth factor. Mol Med Rep 11: 2875-2881, 2015.
2. Guo R, Sherman-Bast C and Abdelmohsen K: miRNA-based ovarian cancer diagnosis and therapy. In: Sarkar F (ed) MicroRNA Targeted Cancer Therapy. Springer, Cham, pp.115-127, 2014.
3. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
4. Horstman E, Mansfield JH, Yekta S, Hu JK, Harfe BD, McKay RA, Martienssen R, Bartel DP and Tabin CJ: The microRNA miR-196 acts upstream of Hoxb8 and Shh in limb development. Nature 438: 671-674, 2005.
5. Boehm M and Slack FJ: microRNA control of lifespan and metabolism. Cell Cycle 5: 837-840, 2006.
6. Tang W, Jiang Y, Mu X, Xu L, Cheng W and Wang X: MiR-153a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression. Cell Signal 26: 1420-1426, 2014.
7. Wang F, Chang TH, Kao CJ and Huang RS: High expression of miR-552-5p, a tumor suppressor, leads to better prognosis in ovarian cancer both in vivo and in vitro. Mol Cancer Ther 15: 1123-1131, 2016.
8. Zhao H, Yu X, Ding Y, Zhao J, Wang G, Wu X, Jiang J, Peng C, Guo GZ and Cui S: MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2. Oncotarget 6: 26457-26471, 2015.
9. Zhao X, Zhou Y, Chen YU and Yu F: miR-494 inhibits ovarian cancer cell proliferation and promotes apoptosis by targeting FGF2R. Oncol Lett 11: 4245-4251, 2016.
10. Hu K and Liang M: Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLC1. In Vitro Cell Dev Biol Anim 53: 149-157, 2016.
11. Xiaohong Z, Lichun F, Na X, Kejian Z, Xiaolan X and Shaosheng W: MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway. Tumour Biol 37: 14989-14997, 2016.
12. Yu S, Fu GB, Tao Z, OuYang J, Kong F, Jiang BH, Wan X and Chen C: MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget 6: 26470-26476, 2015.
13. Guan Y, Yao H, Zheng Z, Qiu G and Sun K: MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer 135: 759-767, 2014.
14. Libório-Kimura TN, Libório TN and Corrêa LE: Identification of microRNAs regulating B7-H3 in breast cancer: The clinical impact of microRNA-29c. Br J Cancer 110: 2072-2080, 2014.
15. Kim JH, Taylor HS, Lu Z, Ladhani O, Hastings JM, Jackson KS, Wu Y, Guo SW and Fazleabas AT: Altered expression of HOXA10 in endometriosis: Potential role in decidualization. Mol Hum Reprod 13: 323-332, 2007.
16. Kelly M, Daftary G and Taylor HS: An autoregulatory element maintains HOXA10 expression in endometrial epithelial cells. Am J Obstet Gynecol 194: 1100-1109, 2006.
17. Daftary GS, Troy PJ, Bagot CN, Young SL and Taylor HS: Direct regulation of beta3-integrin subunit gene expression by HOXA10 in endometrial cells. Mol Endocrinol 16: 571-579, 2002.
18. Cheng W, Liu J, Yoshida H, Rosen D and Naora H: Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 11: 531-537, 2005.
19. Chu MC, Selam FB and Taylor HS: HOXA10 regulates p53 expression and matrigel invasion in human breast cancer cells. Cancer Biol Ther 3: 568-572, 2004.
20. Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du Y, Luo X, Zheng F, Liu R, Zhang H and Ma D: miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer 12: 111, 2012.
21. Carrera M, Buò CC, de Oliveira CE, Cervigno NK, Graner E, Marinucci A, Salo T and Coletta RD: HOXA10 controls proliferation, migration and invasion in oral squamous cell carcinoma. Int J Clin Exp Pathol 8: 3613-3623, 2015.
22. Kim JW, Kim JY, Kim JE, Kim SK, Chung HT and Park CK: HOXA10 is associated with temozolomide resistance through regulation of the homologous recombinant DNA repair pathway in glioblastoma cell lines. Genes Cancer 5: 165-174, 2014.
23. Zhang L, Wan Y, Jiang Y, Ma J, Liu J, Tang W, Wang X and Cheng W: Upregulation HOXA10 homebox gene in endometrial cancer: Role in cell cycle progression. Exp Oncol 31: 32, 2014.